Registrer deg | Logg på | FAQ      [?] 
Recent | Unread | Search | Authors | Tags | Export

pjaspers nsclc [43 articles]

Artikler nylig sendt til pjaspers bibliotek klassifisert med nøkkelordet nsclc. You can also see everyone's nsclc.
  • ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines.
    Proc Natl Acad Sci U S A, Vol. 102, No. 10. (8 March 2005), pp. 3788-3793.
    by JA Engelman, PA Jänne, C Mermel, J Pearlberg, T Mukohara, C Fleet, K Cichowski, BE Johnson, LC Cantley
    posted to akt erbb3 inhibitor iressa nsclc by pjasper on 2007-05-22 18:40:08 as **
  • HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells.
    Cancer Res, Vol. 65, No. 10. (15 May 2005), pp. 4253-4260.
    by A Hirata, F Hosoi, M Miyagawa, S Ueda, S Naito, T Fujii, M Kuwano, M Ono
    posted to egfr erbb2 inhibitor iressa nsclc by pjasper on 2007-05-10 19:52:18 as ***** along with 1 person js229
  • Alteration of the serum levels of the epidermal growth factor receptor and its ligands in patients with non-small cell lung cancer and head and neck carcinoma
    British Journal of Cancer, Vol. aop, No. current. (24 April 2007)
    by Y Lemos-Gonzalez, FJ Rodriguez-Berrocal, OJ Cordero, C Gomez, Paez
    posted to egf ligand nsclc by pjasper on 2007-05-08 20:59:01 as **
  • Erlotinib, an Effective Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Induces p27KIP1 Upregulation and Nuclear Translocation in Association with Cell Growth Inhibition and Cell Cycle Arrest in Human Non-Small Cell Lung Cancer Cell Lines.
    Mol Pharmacol (24 April 2007)
    by Yi-He H Ling, Tianhong Li, Ziqiang Yuan, Missak Haigentz Jr, Thomas K K Weber, Roman Perez-Soler
    posted to inhibito nsclc p27 tarceva by pjasper on 2007-05-08 20:57:30 as **
  • Growth stimulation of non-small cell lung cancer cell lines by antibody against epidermal growth factor receptor promoting formation of ErbB2/ErbB3 heterodimers.
    Mol Cancer Res, Vol. 5, No. 4. (April 2007), pp. 393-401.
    by M Maegawa, K Takeuchi, E Funakoshi, K Kawasaki, K Nishio, N Shimizu, F Ito
    posted to c225 egfr erbb2 erbb3 inhibitor nsclc by pjasper on 2007-05-08 20:50:27 as **
  • Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
    Oncologist, Vol. 12, No. 3. (March 2007), pp. 325-330.
    by LV Sequist
    posted to 2ndgeneration egfr inhibitor nsclc review by pjasper on 2007-05-08 20:37:49 as **
  • Differential constitutive activation of the epidermal growth factor receptor in non-small cell lung cancer cells bearing EGFR gene mutation and amplification.
    Cancer Res, Vol. 67, No. 5. (1 March 2007), pp. 2046-2053.
    by T Okabe, I Okamoto, K Tamura, M Terashima, T Yoshida, T Satoh, M Takada, M Fukuoka, K Nakagawa
    posted to activation egfr mutation nsclc by pjasper on 2007-05-08 18:54:50 as **
  • Epidermal growth factor receptor mutants from human lung cancers exhibit enhanced catalytic activity and increased sensitivity to gefitinib.
    Cancer Res, Vol. 67, No. 5. (1 March 2007), pp. 2325-2330.
    by R Mulloy, A Ferrand, Y Kim, R Sordella, DW Bell, DA Haber, KS Anderson, J Settleman
    posted to egfr iressa mutation nsclc by pjasper on 2007-05-08 18:52:47 as **
  • Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib.
    Ann Oncol, Vol. 18, No. 4. (April 2007), pp. 752-760.
    by F Hirsch, M Varella-Garcia, F Cappuzzo, J McCoy, L Bemis, A Xavier, R Dziadziuszko, P Gumerlock, K Chansky, H West, A Gazdar, L Crino, D Gandara, W Franklin, P Bunn
    posted to amplification egfr inhibitor iressa nsclc by pjasper on 2007-05-08 18:46:53 as **
  • Epidermal growth factor receptor mutations in lung cancer
    Nature Reviews Cancer, Vol. 7, No. 3., pp. 169-181.
    by Sreenath V Sharma, Daphne W Bell, Jeffrey Settleman, Daniel A Haber
    posted to egfr mutation nsclc review by pjasper on 2007-05-08 18:44:57 as ** along with 1 person kochhan
  • p53 enhances gefitinib-induced growth inhibition and apoptosis by regulation of Fas in non-small cell lung cancer.
    Cancer Res, Vol. 67, No. 3. (1 February 2007), pp. 1163-1169.
    by JK Rho, YJ Choi, BY Ryoo, II Na, SH Yang, CH Kim, JC Lee
    posted to apoptosis inhibitor nsclc p53 tarceva by pjasper on 2007-05-08 18:24:35 as **
  • Src-Family Kinases Are Activated in Non-Small Cell Lung Cancer and Promote the Survival of Epidermal Growth Factor Receptor-Dependent Cell Lines
    American Journal of Pathology, Vol. 170, No. 1. (1 January 2007), pp. 366-376.
    by Zhang, Jie, Kalyankrishna, Shailaja, Wislez, Marie, Thilaganathan, Nishan, Saigal, Babita, Wei, Wei, Ma, Long, Wistuba, I Ignacio, Johnson, M Faye, Kurie, M Jonathan
    posted to nsclc src by pjasper on 2007-05-08 18:09:21 as **
  • Update on epidermal growth factor receptor mutations in non-small cell lung cancer.
    Clin Cancer Res, Vol. 12, No. 24. (15 December 2006), pp. 7232-7241.
    by GJ Riely, KA Politi, VA Miller, W Pao
    posted to egfr mutation nsclc review by pjasper on 2007-04-26 17:44:54 as **
  • Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.
    Clin Cancer Res, Vol. 12, No. 23. (1 December 2006), pp. 7117-7125.
    by BA Helfrich, D Raben, M Varella-Garcia, D Gustafson, DC Chan, L Bemis, C Coldren, A Barón, C Zeng, WA Franklin, FR Hirsch, A Gazdar, J Minna, PA Bunn
    posted to akt egfr genomics iressa mutation nsclc by pjasper on 2007-04-26 17:27:15 as **
  • Summary statement: novel agents in the treatment of lung cancer: advances in epidermal growth factor receptor-targeted agents.
    Clin Cancer Res, Vol. 12, No. 14 Pt 2. (15 July 2006)
    by TJ Lynch, AA Adjei, PA Bunn, TG Eisen, J Engelman, GD Goss, DA Haber, JV Heymach, PA Jänne, BE Johnson, DH Johnson, RC Lilenbaum, M Meyerson, AB Sandler, LV Sequist, J Settleman, KK Wong, CS Hart
    posted to erbb inhibitor novel nsclc review by pjasper on 2007-04-25 21:47:09 as **
  • Her2-targeted therapies in non-small cell lung cancer.
    Clin Cancer Res, Vol. 12, No. 14 Pt 2. (15 July 2006)
    by C Swanton, A Futreal, T Eisen
    posted to erbb2 inhibitor nsclc review by pjasper on 2007-04-25 21:46:05 as **
  • The evolving role of cetuximab in non-small cell lung cancer.
    Clin Cancer Res, Vol. 12, No. 14 Pt 2. (15 July 2006)
    by RC Lilenbaum
    posted to c225 nsclc review by pjasper on 2007-04-25 21:45:19 as **
  • Epidermal growth factor receptor inhibitors in development for the treatment of non-small cell lung cancer.
    Clin Cancer Res, Vol. 12, No. 14 Pt 2. (15 July 2006)
    by JV Heymach, M Nilsson, G Blumenschein, V Papadimitrakopoulou, R Herbst
    posted to inhibitor novel nsclc review by pjasper on 2007-04-25 21:44:21 as **
  • Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer.
    Cancer Cell, Vol. 10, No. 1. (July 2006), pp. 39-50.
    by BB Zhou, M Peyton, B He, C Liu, L Girard, E Caudler, Y Lo, F Baribaud, I Mikami, N Reguart, G Yang, Y Li, W Yao, K Vaddi, AF Gazdar, SM Friedman, DM Jablons, RC Newton, JS Fridman, JD Minna, PA Scherle
    posted to adam erbb3 inhibitor nsclc by pjasper on 2007-04-25 21:37:16 as *****
  • Non-small-cell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV_G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272.
    Cancer Res, Vol. 66, No. 13. (1 July 2006), pp. 6487-6491.
    by T Shimamura, H Ji, Y Minami, RK Thomas, AM Lowell, K Shah, H Greulich, KA Glatt, M Meyerson, GI Shapiro, KK Wong
    posted to erbb2 hki-272 mutant nsclc by pjasper on 2007-04-25 21:24:26 as **
  • Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib.
    Clin Cancer Res, Vol. 12, No. 13. (1 July 2006), pp. 3908-3914.
    by DM Jackman, BY Yeap, LV Sequist, N Lindeman, AJ Holmes, VA Joshi, DW Bell, MS Huberman, B Halmos, MS Rabin, DA Haber, TJ Lynch, M Meyerson, BE Johnson, PA Jänne
    posted to deletion iressa mutation nsclc by pjasper on 2007-04-25 21:23:34 as **
  • EGF-independent activation of cell-surface EGF receptors harboring mutations found in gefitinib-sensitive lung cancer
    Oncogene, Vol. aop, No. current.
    by SH Choi, JM Mendrola, MA Lemmon,
    posted to activation egf-independent iressa mutation nsclc by pjasper on 2007-04-25 20:36:12 as **
  • Gene expression patterns that predict sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer cell lines and human lung tumors
    BMC Genomics, Vol. 7 (10 November 2006), 289.
    by Justin M Balko, Anil Potti, Christopher Saunders, Arnold Stromberg, Eric B Haura, Esther P Black
    posted to genomics inhibitor nsclc by pjasper on 2007-04-25 20:18:26 as **
  • Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors.
    Genes Dev, Vol. 20, No. 11. (1 June 2006), pp. 1496-1510.
    by K Politi, MF Zakowski, PD Fan, EA Schonfeld, W Pao, HE Varmus
    posted to iressa mouse mutation nsclc by pjasper on 2007-04-25 20:09:14 as *****
  • Small molecule epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer.
    Ann Oncol, Vol. 17 Suppl 2 (March 2006)
    by T Cascone, MP Morelli, F Ciardiello
    posted to inhibitor iress nsclc review by pjasper on 2007-04-25 19:29:58 as **
  • Anti-EGFR monoclonal antibodies in the treatment of non-small cell lung cancer.
    Ann Oncol, Vol. 17 Suppl 2 (March 2006)
    by A Sartore-Bianchi, G Cerea, I Schiavetto, L Giannetta, R Ricotta, MR Maugeri, M Moroni, G Marrapese, S Siena
    posted to c225 inhibitor nsclc review by pjasper on 2007-04-25 19:29:29 as **
  • Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor.
    Cancer Res, Vol. 66, No. 6. (15 March 2006), pp. 3162-3168.
    by JV Alvarez, H Greulich, WR Sellers, M Meyerson, DA Frank
    posted to mutation nsclc stat3 by pjasper on 2007-04-25 19:21:13 as **
  • Diversity of epidermal growth factor receptor-mediated activation of downstream molecules in human lung carcinomas
    Modern Pathology, Vol. aop, No. current. (28 April 2006)
    by Shioto Suzuki, Satoshi Igarashi, Mitsuhiko Hanawa, Hirochika Matsubara, Akishi Ooi, Yoh Dobashi
    posted to nsclc signaling by pjasper on 2007-04-25 16:41:50 as ** along with 1 person klu
  • Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors.
    Proc Natl Acad Sci U S A, Vol. 103, No. 20. (16 May 2006), pp. 7817-7822.
    by H Ji, X Zhao, Y Yuza, T Shimamura, D Li, A Protopopov, BL Jung, K McNamara, H Xia, KA Glatt, RK Thomas, H Sasaki, JW Horner, M Eck, A Mitchell, Y Sun, R Al-Hashem, RT Bronson, SK Rabindran, CM Discafani, E Maher, GI Shapiro, M Meyerson, KK Wong
    posted to inhibitor nsclc v3 by pjasper on 2007-04-25 16:30:04 as **
  • Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines.
    Cancer Res, Vol. 66, No. 2. (15 January 2006), pp. 944-950.
    by SE Witta, RM Gemmill, FR Hirsch, CD Coldren, K Hedman, L Ravdel, B Helfrich, R Dziadziuszko, DC Chan, M Sugita, Z Chan, A Baron, W Franklin, HA Drabkin, L Girard, AF Gazdar, JD Minna, PA Bunn
    posted to e-cadhering iressa nsclc by pjasper on 2007-04-25 16:19:49 as ** along with 1 person MllePapillon
  • Enhancement of sensitivity to tumor necrosis factor alpha in non-small cell lung cancer cells with acquired resistance to gefitinib.
    Clin Cancer Res, Vol. 11, No. 24 Pt 1. (15 December 2005), pp. 8872-8879.
    by K Ando, T Ohmori, F Inoue, T Kadofuku, T Hosaka, H Ishida, T Shirai, K Okuda, T Hirose, N Horichi, K Nishio, N Saijo, M Adachi, T Kuroki
    posted to iressa nsclc tnf by pjasper on 2007-04-19 19:40:33 as **
  • EKB-569, a new irreversible epidermal growth factor receptor tyrosine kinase inhibitor, with clinical activity in patients with non-small cell lung cancer with acquired resistance to gefitinib.
    Lung Cancer, Vol. 51, No. 3. (March 2006), pp. 363-368.
    by N Yoshimura, S Kudoh, T Kimura, S Mitsuoka, K Matsuura, K Hirata, K Matsui, S Negoro, K Nakagawa, M Fukuoka
    posted to ekb569 inhibitor iressa nsclc by pjasper on 2007-04-19 19:23:32 as **
  • Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer.
    Clin Cancer Res, Vol. 11, No. 23. (1 December 2005), pp. 8288-8294.
    by EB Haura, Z Zheng, L Song, A Cantor, G Bepler
    posted to nsclc stat3 by pjasper on 2007-04-19 19:20:25 as **
  • HER3 genomic gain and sensitivity to gefitinib in advanced non-small-cell lung cancer patients
    British Journal of Cancer, Vol. aop, No. current. (15 November 2005)
    by F Cappuzzo, L Toschi, I Domenichini, S Bartolini, GL Ceresoli, E Rossi, V Ludovini, A Cancellieri, E Magrini, L Bemis, WA Franklin, L Crino, PA Bunn, FR Hirsch, M Varella-Garcia
    posted to amplification erbb3 iressa nsclc by pjasper on 2007-04-19 19:14:37 as **
  • Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers.
    Int J Cancer, Vol. 118, No. 2. (15 January 2006), pp. 257-262.
    by H Shigematsu, AF Gazdar
    posted to mutation nsclc review by pjasper on 2007-04-19 19:04:08 as **
  • Cooperative cell-growth inhibition by combination treatment with ZD1839 (Iressa) and trastuzumab (Herceptin) in non-small-cell lung cancer.
    Cancer Lett, Vol. 230, No. 1. (8 December 2005), pp. 33-46.
    by H Nakamura, S Takamori, T Fujii, M Ono, H Yamana, M Kuwano, K Shirouzu
    posted to herceptin inhibitor iressa nsclc by pjasper on 2007-04-19 19:02:16 as **
  • Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR
    Nature Genetics, Vol. 37, No. 12. (30 October 2005), pp. 1315-1316.
    by Daphne W Bell, Ira Gore, Ross A Okimoto, Nadia Godin-Heymann, Raffaella Sordella, Roseann Mulloy, Sreenath V Sharma, Brian W Brannigan, Gayatry Mohapatra, Jeff Settleman, Daniel A Haber
    posted to iressa mutation nsclc t790m by pjasper on 2007-04-19 19:00:48 as **
  • Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials.
    J Clin Oncol, Vol. 23, No. 31. (1 November 2005), pp. 8081-8092.
    by DW Bell, TJ Lynch, SM Haserlat, PL Harris, RA Okimoto, BW Brannigan, DC Sgroi, B Muir, MJ Riemenschneider, RB Iacona, AD Krebs, DH Johnson, G Giaccone, RS Herbst, C Manegold, M Fukuoka, MG Kris, J Baselga, JS Ochs, DA Haber
    posted to amplification iressa mutation nsclc by pjasper on 2007-04-18 21:08:24 as **
  • Targeting multiple signal transduction pathways in lung cancer.
    Clin Lung Cancer, Vol. 7 Suppl 1 (September 2005)
    by AA Adjei
    posted to inhibitor nsclc review by pjasper on 2007-04-18 20:49:17 as **
  • Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations.
    J Natl Cancer Inst, Vol. 97, No. 16. (17 August 2005), pp. 1185-1194.
    by T Mukohara, JA Engelman, NH Hanna, BY Yeap, S Kobayashi, N Lindeman, B Halmos, J Pearlberg, Z Tsuchihashi, LC Cantley, DG Tenen, BE Johnson, PA Jänne
    posted to c225 iressa nsclc by pjasper on 2007-04-18 20:44:20 as read
  • Epidermal growth factor receptor mutations in patients with non-small cell lung cancer.
    Cancer Res, Vol. 65, No. 17. (1 September 2005), pp. 7525-7529.
    by BE Johnson, PA Jänne
    posted to mutation nsclc review by pjasper on 2007-04-18 20:41:05 as **
  • Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients.
    J Clin Oncol, Vol. 23, No. 22. (1 August 2005), pp. 5007-5018.
    by F Cappuzzo, M Varella-Garcia, H Shigematsu, I Domenichini, S Bartolini, GL Ceresoli, E Rossi, V Ludovini, V Gregorc, L Toschi, WA Franklin, L Crino, AF Gazdar, PA Bunn, FR Hirsch
    posted to amplification erbb2 iressa nsclc by pjasper on 2007-04-18 20:38:35 as ***
  • Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer.
    J Clin Oncol, Vol. 23, No. 28. (1 October 2005), pp. 6829-6837.
    by T Takano, Y Ohe, H Sakamoto, K Tsuta, Y Matsuno, U Tateishi, S Yamamoto, H Nokihara, N Yamamoto, I Sekine, H Kunitoh, T Shibata, T Sakiyama, T Yoshida, T Tamura
    posted to iressa mutation nsclc by pjasper on 2007-04-18 19:31:19 as ***
    • NB: Du kan sitere denne siden som: http://www.citeulike.org/user/pjasper/tag/nsclc

    RIS BibTeX
    CiteULike organises scholarly (or academic) papers or literature and provides bibliographic (which means it makes bibliographies) for universities and higher education establishments. It helps undergraduates and postgraduates. People studying for PhDs or in postdoctoral (postdoc) positions. The service is similar in scope to EndNote or RefWorks or any other reference manager like BibTeX, but it is a social bookmarking service for scientists and humanities researchers.